Results from a pivotal Phase 3 trial evaluating pembrolizumab as adjuvant therapy for completely resected stage IIB or IIC melanoma were published on 2024-01-01. The study, known as KEYNOTE-716, compared pembrolizumab with placebo in this patient population.
Background
Pembrolizumab is an immunotherapy drug. The KEYNOTE-716 trial investigated its use as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma, a population at high risk of recurrence after surgery.
Trial design
The KEYNOTE-716 study was a randomised, double-blind, phase 3 trial designed to assess pembrolizumab as adjuvant therapy. It compared pembrolizumab against placebo in patients who had undergone complete surgical resection of their stage IIB or IIC melanoma.
What this means
The publication of the KEYNOTE-716 trial results provides important data for clinicians and researchers focused on melanoma treatment. This Phase 3 study explored the potential of pembrolizumab as an adjuvant therapy following complete surgical resection for patients with stage IIB or IIC melanoma, a group with a significant risk of disease recurrence. The findings will contribute to the understanding of immunotherapy's role in preventing recurrence in this high-risk population.
Source
The information regarding this trial publication was sourced from PubMed, an authoritative database of biomedical literature. The publication, titled "Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial," was made available on 2024-01-01 via pubmed.ncbi.nlm.nih.gov.